<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jeremy Jones(Mayo Clinic in Florida), Axel Grothey(Campbell Clinic), Humaid O. Al‐Shamsi(Mayo Clinic in Arizona), Lindsay A. Renfro(Mayo Clinic in Arizona), Ben Y. Zhang(Mayo Clinic in Arizona), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Andrew Rankin(Mayo Clinic in Arizona), James Sun(GlobalFoundries (United States)), Benjamin R. Kipp(Mayo Clinic in Arizona), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Alexis D. Leal(Mayo Clinic in Arizona), Alexa B. Schrock(GlobalFoundries (United States)), Pashtoon Murtaza Kasi(Cornell University), Jeffrey S. Ross(Unknown), Siraj M. Ali(UPMC Hillman Cancer Center), Robert R. McWilliams(Mayo Clinic in Arizona), Jesse S. Voss(Mayo Clinic in Arizona), Scott Kopetz(The University of Texas MD Anderson Cancer Center)
Cited by 357
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k